The impact of networking on innovative performance of new biotechnology firms: a combined econometric and scientometric analysis. by Debackere, Koenraad & Clarysse, B
DEPARTEMENT TOEGEPASTE 
ECONOMISCHE WETENSCHAPPEN 
ONDERZOEKSRAPPORT  NR  9748 
THE IMPACT OF  NETWORKING ON INNOVATIVE 
PERFORMANCE OF NEW BIOTECHNOLOGY FIRMS: A 
COMBINED ECONOMETRIC AND SCIENTOMETRIC 
ANALYSIS 
by 
K.  DEBACKERE 
B.  ClARYSSE 
Katholieke Universiteit Leuven 
Naamsestraat 69,  8-3000  Leuven ONDERZOEKSRAPPORT  NR  9748 
THE IMPACT OF  NETWORKING ON  INNOVATIVE 
PERFORMANCE OF  NEW BIOTECHNOLOGY FIRMS: 




K.  DEBACKERE 
B.  CLARYSSE THE IMPACT OF  NETWORKING  ON  INNOVATIVE  PERFORMANCE  OF  NEW 
BIOTECHNOLOGY  FIRMS: 
A  COMBINED  ECONOMETRIC AND  SCIENTOMETRIC  ANALYSIS 
BY 
KOENRAAD  DEBACKERE,  K.U.LEUVEN, NAAMSESTRAAT  69,  B-3000  LEUVEN 
BART CLARYSSE, U. GENT, BELLEVUE  6,  B-9050  GENT THE IMPACT OF  NETWORKING  ON  INNOVATIVE  PERFORMANCE  OF  NEW 
BIOTECHNOLOGY  FIRMS: 
A  COMBINED  ECONOMETRIC AND  SCIENTOMETRIC  ANALYSIS 
ABSTRACT 
2 
This paper examines the impact of firm  resources  and network capabilities on  innovative 
performance in a popuiation of  i i 7 biotech companies. After controlling for the traditional 
size  and  scope  effects,  the  managerial  focus  of  the  firms'  R&D  activities  and  their 
collaboration activities with external partners (in majority universities) become the central 
variables in our study. A (unbalanced) panel analysis of the firms over a twenty-year period 
shows the highly significant impact of research focus and networking activities on innovative 
performance. THE IMPACT OF  NETWORKING  ON  INNOVATIVE  PERFORMANCE  OF  NEW 
BIOTECHNOLOGY  FIRMS: 
A  COMBINED  ECONOMETRIC AND  SCIENTOMETRIC  ANALYSIS 
INTRODUCTION 
3 
For many new technology based firms,  innovative productivity is directly related  to their 
competitive position in the  industry.  Rrms with a larger innovative  output enhance their 
reputation and may hence be better able to compete for resources in the financial, scientific 
and corporate community. An extensive body of empirical research on the determinants of 
innovative output at the firm level exists in industrial economics (Cohen and Levin, 1988). In 
the wake of Schumpeter (1939), this stream of research has mainly focused on the question 
whether size influences innovative output. This research has shown that innovative output 
increases with size below a certain "threshold" (Cohen,  Levin and Mowery, 1987; Scherer, 
1980).  In other words,  companies should obtain a "critical mass" before they can innovate 
efficiently. 
More recently, the resource-based theory of the firm (Dierickx and Cool,  1989; Wernerfelt, 
1984) as well as the dynamic capabilities framework (Amit and Shoemaker, 1993; Teece and 
Pisano, 1994; Teece,  Pisano and Shuen, 1994), have offered a new theoretical perspective 
on how companies develop competitive advantages. The former perspective emphasizes 
the competitive impact of accumulated stock of non-imitable or non-transferable resources; 
the latter points to the firm's capabilities to deploy these resources and develop new ones as 
sources of competitive advantage. 
This paper starts from the resource-based  and  dynamic  capability concepts  to explain 
innovative performance of new technology firms in the U.S.  biotech industry. The biotech 
industry offers  a  particularly  interesting  area  to  study  these  issues  since  innovative 
productivity is directly linked to economic returns for most biotech companies.  Even in 1995, 
very few biotech companies created value through own product sales (Ernst & Young, 1995). 
Hence, instead of marketing or manufacturing capabilities, research competencies determine 
the competitive  advantage  of  these  dedicated  biotech  firms.  A  unique  database  was 
constructed  which  represents  an  unbalanced  panel  of  US  biotech  firms  that could  be 
identified in bibpharmaceutical research with more than fifty employees during the period 
1982-1994. Data was collected from various sources such as lSI, U.S. Patent Office, BioScan, 
the NDA-pipeline, Compustat,  10-K reports,  American Hospital and  Healthcare Index, and 
Dibner's Guide to biotech companies. 4 
HYPOTHETICAL  FRAMEWORK 
Following Henderson and Cockburn's research (1994), we measure the stock of knowledge 
in each of these firms as  the  cumulated number of patents and the cumulated number of 
research dollars invested, both net of depreciation. Innovative performance is measured as 
the number of filed US patents during each year of observation. Consistent with the literature 
on economies of scale in pharmaceutical research, the flow of knowledge is measured as the 
annual level of research expenditures (Jensen, 1987; Graves and Langowitz, 1993). Dynamic 
capabilities are elaborated in two ways.  Rrst, we look at how research is organized internally. 
Rrst, we distinguish between companies that are focused or not.  It has been argued in the 
R&D management literature that research focus enhances performance (Woiceshyn, 1995). 
Second, we distinguish between those firms that organize their research in a functional way 
and those that use a market-based approach (based on Allen's input- and output-orientation 
in R&D matrices, 1986). 
Following previous work on  knowledge spill-overs, we also include the location in the model 
by distinguishing between those companies that are located in the Route 128 Boston area or 
San Francisco Bay and those that are not (Saxenian, 1994). 
In addition, we focus on the ability that research organizations have developed to collaborate 
(on  research)  with  external  partners  (mainly universities  and  other biotech  firms).  This 
hypothesis is  derived from the large literature which  has  focused  on  the  emergence  of 
research networks in  biotechnology (della Valle and  Gambardella,  1993;  Freeman,  1991; 
Pisano, Shan and Teece,  1988; Powell and Brantley, 1992). 
Industrial  organization  and  innovative  productivity. A first  hypothesis  is  derived 
from the extensive body of literature on industrial economics which has concentrated on the 
relationship between innovation and size (e.g. Acs and Audretsch,  1990; Cohen and  Levin, 
1988; Kamien and Schwartz,  1982). Although inconclusive on  Schumpeter's hypothesis, 
this stream of research converges on the idea that innovative productivity increases with size 
up to a certain threshold (Cohen et aI.,  1987; Graves and Langowitz, 1993; Scherer, 1965). 
Scherer (1980)  concluded that the firms  which foster innovation ideally should obtain a 
critical mass of about 250-400 million dollar (1978-dollars) in sales, a revenue range where 
most biotech companies only can dream of. Hence, we hypothesize that: 
Hypothesis  1:  Innovative  productivity  in  new  biotech  firms  is  a  positive 
function  of firm  size. 5 
A second hypothesis, concerns the marginal productivity or elasticity of R&D expenditures 
(Hausman, Hall and Griliches, 1984; Henderson and Cockburn, 1995; Jensen,  1987). The 
main question of interest in these studies has been to determine the  elasticity of patents 
with respect to R&D expenditures. Most studies find that there are economies of scale at the 
research level, though most probably at a decreasing rate. 
Graves  and  Langowitz  (1993:  603)  find  that  the  expected  elasticity  does  not  differ 
significantly from 1 for pharmaceutical firms that report an R&D expenditure which is minimum 
25% below the mean. The average biotech R&D expenditures are well below Graves and 
Langowitz' average industry mean of 1443 million dollars (in constant 1994 $). Hence: 
Hypothesis  2:  After  controlling  for  firm  size,  a  positive  influence  of  annual 
R&D  expenditure  on  innovative  productivity  with  an  elasticity 
which  does  not differ from  1,  is  hypothesized. 
The  resource-based  theory  of the  firm. The  resource  based  tradition  goes  back to 
Penrose's  analysis  of  firm  growth  (1959).  Rumelt  (1974)  was  an  early  adopter  of  her 
pioneering ideas and has implemented them in a theory of differentiation. Wernerfelt (1984) 
redirected  the  attention  towards  Penrose's original  resource  based  explanation  of firm 
growth.  He  added the imperfect working  of markets as  a critical element in  explaining how 
resources generate competitive advantage. Resources are only valuable if they are difficult to 
trade or imitate on the spot market. Subsequent contributions have made a further distinction 
between  "resources" and  "capabilities" (Amit and  Schoemaker,  1993;  Foss  and  Eriksen, 
1995; Henderson and  Cockburn,  1994; Nelson,  1991; Teece,  Pisano  and  Schuen,  1991). 
Resources are the "strategic assets" which companies have accumulated in the past while 
capabilities represent their ability to deploy and rebuild these resources. 
We follow Amit and Schoemaker's definition of resources (1993) as "stocks of available factors 
owned or controlled by the firm", One factor of tremendous importance for a new technology 
based firm is its stock of knowledge.  In  many instances, a new technology based startup's 
only valuable asset is its knowledge stock.  The value of knowledge in biotech  and,  more 
generally,  in  modern  pharmaceutical  research  has been  documented  by many studies 
(Henderson and Cockburn, 1994; della Valle and Gamberdella, 1993). Hence hypothesis 3 is 
formulated as follows: 
Hypothesis  3:  After  controlling  for  firm  size  and  annual  R&D  expenditures, 
innovative  productivity  is  hypothesized  to  be  an  Increasing 
function  of the  knowledge that  a  company  has  accumulated. 6 
However. it would be too optimistic to attribute all differences in innovative productivity to the 
stock of knowledge which has been built up in-house. The increasingly complex process of 
drug discovery has forced many organizations to enter collaborations with partners which 
have complementary research strengths or strategies (IMS Market Letter. 1992). Especially 
in  the biotech industry. the  emergence of research  collaborations is prominent  and  well-
documented  (Arora and  Gambardella.  1990; Barley et  aL.  1992; Debackere et aL.  1996; 
Pisano et aL.  1988; Powell et aL.  1995). Though. organizations should learn how to deal with 
external  partners and  to develop  "routines" which  make  them  efficient  participants  in  a 
research network. These learned patterns of inter-firm collaborations coincide with Nelson 
and  Winter's (1982) evolutionary theory of organizational routines.  Hence.  hypothesis 4 is 
stated as follows: 
Hypothesis  4:  After  controlling  for  firm  size  and  annual  R&D  expenditure, 
innovative  productivity  is  an  increasing  function  of  the 
routines  the  firm  has  developed  to  deal  with  external 
partners. 
Dynamic capabilities in the management of knowledge  stocks.  Companies  that 
are able to proceed more quickly in the identification and isolation of lead compounds are 
most likely to  be winners in the biotech industry. Research in such new technology based 
companies is sometimes organized in a way to increase the speed of product development. 
regardless the risk factor involved (Christoffersen and  Marr.  1995; Spilker. 1989). Literature 
that  has focused  on the management of  drug  discovery has described two extremes of 
organizational  approaches:  a disciplineltechnology versus  a therapeutic  organizational 
structure (Christoffersen and  Marr.  1995:27). A disciplineltechnology-based organizational 
structure has been hypothesized to be useful if the disciplineltechnology is rapidly evolving 
(Allen. 1986). This organizational approach has been called input-oriented. A second "pure" 
form of organization is the therapeutic or output focused organization (Allen.  1986).  In this 
type of organization.  there is  a clear focus on  the therapeutic targets of interest.  These 
therapeutic targets are likely to be  accomplished through  a variety of technologies.  Large 
organizations try to balance both approaches through the matrix structure (Katz and Allen. 
1985). 
Case study research examining successful and less successful new technology based firms 
has identified ''focus'' as  a critical success factor, regardless whether this focus is input- or 
output-oriented  (Woiceshyn.  1995).  Along  these lines of thought,  it seems questionable 
whether the consolidation or merger of different biotechnology firms is beneficial in terms of 
research productivity.  Literature on  mergers suggests an  increased coordination costs to direct research efforts off-setting many hypothesized benefits of such mergers (Folta and 
Leiblein, 1994). Especially if two firms are located in different geographical areas, it might be 
difficult to obtain the empowered team-spirit which characterizes most successful product 
development teams (Katz, 1993). 
Based on these arguments, we hypothesize that: 
7 
Hypothesis  5:  After  controlling  for  firm  size  and  annual  research 
expenditure,  companies  of  which  the  research  efforts  are 
focused  around  a  particular  technology  or disease  are  more 
productive  than  those  without  focus. 
Corollary  5:  Given  the  life-cycle  position  of  most  biotechnological 
developments,  input-oriented  organization  forms will  be more 
productive  than  output-oriented  forms. 
Rnally, we focus on the implicit or explicit choice which a company makes about its location. 
Both the economic and  management literature has recently focused on the importance of 
knowledge  spillovers  in  high  technology  industries  (Griliches,  1991;  Kenny,  1986; 
Saxenian, 1994). Jaffe et al. (1993) found that these spillovers are geographically localized. 
In  his  analysis  of  Vertex,  Werth  (1994)  describes  how  the  company  founder,  Boger, 
purposefully decided to locate his company in the Boston area close to Harvard, MIT and the 
Whitehead Institute. Hence: 
Hypothesis  6:  After  controlling  for  firm  size  and  annual  research 
expenditure,  companies  located  in  regions  subject  to  many 
knowledge  spillovers  will  be  more  productive  than  those 
that  are  not. 
RESEARCH  SITE:  THE  BIOTECH  INDUSTRY 
We have restricted our study to a new biotechnology firms characterized as biopharmaceutical 
companies;  consistent  with  the  "Center  for  the  Study  of  Drug  Development  at  Tufts 
University," biopharmaceuticals are defined as "therapeutic protein drugs or imaging agents, 
derived either through recombinant DNA techniques (rONA products) or through hybridoma 
technology (monoclonal antibodies, Mabs)." 
Panel  data  were  collected  from  1971  onwards  (the  founding  year  of  Cetus,  generally 
considered to be the first new  biotechnology start-up),  using  a wide variety of public and 
bibliographic data sources. Major data sources were: patent and publication data from the U.S. 
Patent Office and  lSI respectively; BioSean  (1985-1994); Dibner's Guide to  Biotechnology 
(1988/1991/1993)  and.  finally.  the  NDA-pipeline  for the  period  1982-1994.  In  line  with 8 
previous industrial economics approaches (e.g. Scherer,  1980), the database was limited to 
companies with at least 50 employees in a given year. This criterion stems from the fact that 
data on companies with less than 50 employees tends to be highly unreliable and incomplete. 
The  database used in  the  analyses  reported  below covers the  period  1982-to-1994.  It 
contains 642 observations, representing 118 firms. 
Variabies. The dependent variable is  the number of patent applications filed  at  the U.S. 
Patent Office. The Industrial Organization variables are EMPLOYEE and RESEARCH. We use 
the number of employees as an indicator of size rather than their annual sales or revenue level 
(Jensen,  1987; Graves and langowitz, 1993). There are two reasons which favor the use of 
employees in our case. Rrst, it has been argued that the number of employees as a proxy for 
size  regards  size in  terms of  capacity,  while  annual  sales measure the  scale of current 
operations {Sarron et aI.,  1994}. Second, new technology based firms may obtain substantial 
amounts of funding  from sources that  are  not  included  in  the  annual  income statement. 
Therefore, the actual size of a company would be underestimated if the annual revenue level 
was used. The scale of the firm's research level is measured by its R&D-spending that year. 
We  deflate  this  variable  by  using  the  PPI  (Producer's  Price  Index)  for  proprietary 
pharmaceutical preparations. 
In order to test the resource-based hypotheses, three variables were constructed. CUMPAT 
stands for the cumulative number of patents,  net of depreciation. Whereas CUM PAT is a 
proxy for the stock of knowledge on the innovative output side, CUMRES stands for the stock 
of  knowledge  measured at the input level.  Rnally,  REXP is a proxy for the organizational 
routines organizations have developed in dealing with external research partners, measured 
as the number of years a company has been involved in research collaborations, as we could 
re-construct them from the various bibliographic data sources used. 
The variable COlLAS takes on the value of 1 in a given year when the company is involved in 
a collaboration agreement with another organization. The other dynamic capability variables 
are  MARKET, TECH and MERGER. TECH and MARKET capture  the functional  (input-
oriented) or therapeutic (output-oriented) form of research organization. Information from the 
NDA-pipeline was used to construct this variable.  MERGER is a dummy variable to indicate 
whether the company is a merged one or not, hence pointing to the potential integration of 
research teams. 
Rnally, we define the location of the  company.  In the initial database, the exact location of 
each company is included. A dummy was constructed to indicate whether the company was 
located in the Boston area or in the San Francisco Say area. 9 
MODEL  SPECIFICATION 
Consistent with  Henderson  and  Cockburn (1994&1995), we hypothesize that patents are 
generated by a production function  Y=f(X,bJ, where X is a vector of the drug discovery input 
variables and b is a vector of parameters. 
As the dependent variable is a count measure (i.e., an integer truncated at 0), we model the 
probability that n patents will be filed by a certain company in a particular year. In line with other 
studies which have analyzed discrete variables as innovative output variables, we assume that 
the counts are generated by a Poisson process (Graves and  Langowitz, 1993; Hausman et 
aI.,  1984; Henderson and Cockburn,  1994&1995; Jensen, 1987). The basic Poisson model 
for event count data can be described as: 
y~ 
-J..(x~)  J..(x ~ ) 
Pr(Y  it  - y  )  - e  [ 
~  y  ! 
~ 
To incorporate the explanatory variables, Lambda is made a function of the covariates, which 
generates equation: 
where b are the coefficients, X are the explanatory variables, i is the }h variable,  t is the ,th time 
period and j is the}h company.  The Poisson model holds the strong assumption that both 
the variance and the mean are equal.  Because of these potential problems that arise when 
using the Poisson specification as the only model, we have analyzed the model's robustness 
by comparing the results obtained in the Poisson model with those in the Negative Binomial. 
RESULTS 
Table  1  shows  the  various  models  tested.  Consistent  with  the  Industrial  Organization 
literature, we started with the size and research scale variables and  a time trend. This time 
trend  has  been  included  in  most  of the  previous  (time  series)  studies  on  innovative 
productivity (e.g.  Graves  and  Langowitz,  1993; Hausman  et  aI.,  1984;  Henderson  and 
Cockburn,  1994&1995; Jensen,  1987). We  find  an  inverted U-shaped relationship for this 
time trend, indicating that innovative productivity has started to slow down. 10 
The analyses suggest that there are high, though decreasing, returns to scale to be gained 
from an increase in absolute size of the company. As a general conclusion, we can state that 
hypothesis  1,  relating  size  to  innovative output.  receives full support; with  size explaining 
already 33% of the variance in innovative productivity. The elasticity of R&D  expenditures, 
after controlling for size,  is somewhat more difficult to interpret. Since this variable is rather 
strongly  correlated  with  EMPLOYEE  (r=0.76),  the  results  should  be  treated  with  some 
caution. After controlling for firm size, only a small effect of annual research expenditures on 
innovative  productivity remains.  To  compute the change in slopes.  we further divided the 
sample in  four parts, using  age quartiles as  a cut-off point: the 25% quartile is 4 years. the 
median age is 6 years and  the 75% quartile is 9 years.  Interestingly, the magnitude of the 
slope of LNDERES changed as follows over the subsequent intervals: 0.47 in the first interval. 
0.11  in the second quartile, 0.02 in the third quartile and finally 0.01  for the oldest 25% of the 
companies. This significant drop in slope is surprisingly. at least. 
There are  a number of explanations which  can  be given for this observation.  Rrst. biotech 
companies may, early in their life-cycle, pursue patents as a research outcome; later on their 
R&D  expenses turn  towards  the  development  of  this  patented  knowledge  in  products. 
Second,  new biotech  companies  often  are  able  to  attract researchers  which  bring  along 
"ready-to-patent"  knowledge.  Third.  there  may  be  decreasing marginal  returns to patent 
productivity. 
Our  findings  further confirm  the  hypothesis that  both  resource-based  explanations  and 
dynamic capabilities play an important role in explaining differences in innovative productivity. 
As  shown  in  the  models,  the  cumUlative  number  of  research  dollars  invested  (net  of 
depreciation)  has some effect on  innovative productivity; while the  cumulative number of 
patents does significantly affect innovative productivity. atter controlling for the IO-variables. 
Additional analyses suggest that biotech firms. after controlling for increases in firms size. are 
very much dependent upon the "quality"of the people whom they hire (which is reflected in 
the  stock  of  knowledge  measured  on  the  output  side,  but  not  on  the  input  side). 
Researchers, who already have a name in the field or are very close to patenting. significantly 
increase the productivity of those firms. 
We further analyze whether the routines the organization has developed to deal with external 
partners contribute to its research productivity. From the analyses. we can conclude that the 
routines  developed  to  collaborate  with  external  partners  significantly  contribute  to  the 
innovative productivity of an organization, regardless its size. 11 
Rnally, we investigate the hypotheses that dynamic capabilities, or the abilities  a firm has to 
organize its research activities at a certain period in time, influence its innovative productivity. 
Hypothesis 5 receives full support, indicating that integration of the research activities is a very 
important explanation of differences in innovative output.  Both  the  MARKET and  TECH 
variables are significantly different from 0, which indicates that having a focus is always better 
than having no focus (although in 50% of the observations, no focus is available). In order to 
further test hypothesis 5,  we  perform a test on the linear combination of the coefficients of 
TECH and MARKET. As expected, the combination of coefficients was different from 0 at the 
p<O.01. 
Taken  at  face value,  the most important variable seems to be TECH,  which captures the 
organization of research activities around one particular technology. The slope of this variable 
is 0.705, in comparison to 0.368 for the MARKET variable. A Hest on the slope coefficients 
supported this speculation. 
Further elaborating on hypothesis 5,  merged companies are significantly less productive than 
the  not-merged  ones.  Again,  this  result  supports  hypothesis  5,  stating  that  research 
integration is an  important factor to foster research productivity. The literature on  mergers 
mostly mentions the high coordination costs which accompany these transactions. Especially 
in a research environment, where know-how is intangible, mergers may not work very well. 
Rnally, the LOCATION of the company was entered  as  a separate variable in the model. 
Although this is a very rude proxy to capture spillovers, the coefficient was (surprisingly) not 
significant. 
Rnally, we explored  how sensitive the results are to the Poisson assumption. The results 
using a Negative Binomial approach were highly comparable to the  Poisson model,  thus 
confirming the robustness of the previous findings. 
CONCLUSION 
After controlling  for the traditional  Industrial  Organization  hypotheses,  we  showed  how 
hypotheses derived from the resource-based  theory of the firm and the dynamic capability 
framework can  explain innovative performance.  More specific, external collaborations are 
found to be very important to increase innovative productivity.  In this case, there are strong 
returns to learning. Although about one fourth of our sample is currently involved in a kind of 
formal research agreement, not all  of them have sufficiently developed the  organizational 
structures to successfully exploit these arrangements. The findings on external collaboration 12 
show how organizations should develop certain routines or build up certain resources before 
they can fully exploit the dynamic capabilities. 
Consistent with qualitative research, we find that having a R&D focus is extremely important in 
reaching an  optimal level of innovative productivity. In this stage of the biotech life-cycle, a 
technology focus still seems more important than a market focus. 
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TABLE  1 
Results of Poisson Regressions on Patent Productivity 
Variables  (1)  (2)  (3) 
Intercept  -6.247**  -7.511**  -8.33** 
Log( Employees)  0.613**  0.077**  0.324** 
Log(Research $)  0.042*  0.085  0.095 
CUMPAT  0.004**  0.012** 
Log(CumRes $)  -0.029  0.100* 
REXP  0.095** 
MARKET  0.313** 
TECH  0.637** 
MERGER  -1.11** 
COLLAB  -0.226 
LOCATION  0.076 
TIME  0.871 **  0.705**  1.263** 
TIME*TIME  -0.0458**  -0.039**  -0.068** 
R2  0.33  0.36  0.44 
*: p<O.05 -- **: p<O.01  /1117 new biotechnology firms II period of observation: 1982-1994. 
Applying a Negative Binomial leads to robust results. 